Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

Clinical and Molecular Allergy

Malik Ghannam¹  Brent Berry¹  Praful Kelkar²  Rachel Husmann³  John B. Davies⁴ 

[1] Department of Neurology, University of Minnesota;Minneapolis Clinic of Neurology;University of Minnesota;VitreoRetinal Surgery, PA;

关键词: Multiple sclerosis;    Fingolimod;    Retina;    Macular edema;    Nonsteroidal anti-inflammatory eye drops;   

DOI  :  10.1186/s12948-020-00119-4

来源: DOAJ

【 摘 要 】

Abstract Background Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops. Case presentation A 38-year-old Caucasian female patient with history of relapsing–remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod. Conclusion FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up.

【 授权许可】

Unknown